Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Caraco Pharma Q2 net sales rise
Caraco Pharma has posted a net loss of $1.51m for the second quarter 2010, or $0.04 loss per diluted share, compared to net income of $6.67m, or $0.16
Caraco Pharma has posted a net loss of $1.51m for the second quarter 2010, or $0.04 loss per diluted share, compared to net income of $6.67m, or $0.16
Dyadem claimed that it has expanded in response to a surge in customer demand in the EU for its enterprise risk management software and services amid heightened scrutiny
Prior to joining Medivir, Edenius served as senior vice president and chief scientific officer of Swedish pharmaceutical company Orexo. Edeniuss has also worked as the vice president and
Sufentanil TDS is a matrix-type transdermal patch with the active ingredient sufentanil, a highly potent opioid analgesic that is used as an injection or infusion for anesthesia and
Valino served as an operating partner with Advent International, a global private equity firm, where he focused on investment opportunities in the Latin American health care industry. From
CTI said that the application submission follows a positive opinion from the EMA’s Pediatric Committee (the PDCO), where PDCO agreed to CTI’s Pediatric Investigation Plan (PIP) for Pixuvri.
The safety and effectiveness of Teflaro was evaluated in four, Phase 3 clinical trials in patients ages 18 years and older (two each in CABP and in ABSSSI).
Helix BioPharma said that the product revenue contributed to the increase in revenue in fiscal 2010 when compared to fiscal 2009 and was offset slightly by a decrease
Gilead’s three-arm Phase IIa trial evaluated the safety and efficacy of GS 9190, an oral polymerase inhibitor, in combination with GS 9256, an oral protease inhibitor, when used
Study 204 was a randomised, double-blind, placebo-controlled, two arm study of a single oral dose of 600 mg of NXN-188 for the treatment of moderate to severe acute